Cipla joins hands with Novartis Pharma AG to market diabetes drug Galvus in India Ruchika Sharma10 April 2023 3:10 PM ISTGalvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication...
Novartis Entresto receives positive CHMP opinion for pediatric heart failure Ruchika Sharma2 April 2023 2:00 PM ISTPediatric heart failure represents an important cause of morbidity and mortality in childhood.
Novartis buoyed by trial success in early-stage breast cancer Ruchika Sharma29 March 2023 9:15 AM ISTFrankfurt: Novartis's Kisqali breast cancer drug cut the risk of recurrence in women who were diagnosed at an early stage of the disease in a pivotal...
Novartis gets CDSCO panel nod for Phase III CT of anticancer drug Ianalumab Dr. Divya Colin23 March 2023 6:00 PM ISTNew Delhi: In a significant development, pharmaceutical major Novartis has got the go-ahead from the Subject Expert Committee (SEC) functional under...
Novartis halts UK trial of anticholesterol drug Leqvio Dr. Nandita Mohan23 March 2023 6:00 PM ISTNovartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of...
Health Bulletin 23/March/2023 Dr. Nandita Mohan23 March 2023 4:25 PM ISTHere are the top health stories for the day:New Bond Policy: Gujarat proposes 1.5 years of mandatory service for doctors completing MBBS, PG...
Novartis not to move ahead with UK trial of anti-cholesterol drug Leqvio Ruchika Sharma22 March 2023 4:00 PM ISTBerlin: Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally...
Novartis secures USFDA nod for Tafinlar plus Mekinist for pediatric brain cancer Ruchika Sharma17 March 2023 2:35 PM ISTLow grade glioma is the most common pediatric brain cancer.
Novartis launches new USD 11 billion share buyback Ruchika Sharma13 March 2023 10:00 AM ISTZurich: Novartis has formally launched its new share buyback programme where it could spend up to 10 billion Swiss francs ($10.90 billion)...
Novartis, Teijin Pharma ink pact for preclinical candidate for proteinuric kidney diseases Ruchika Sharma8 March 2023 3:30 PM ISTTeijin Pharma will receive an upfront cash payment of USD 30 million from Novartis and is eligible to receive potential development and commercial...
Novartis names Gilbert Ghostine as Chairman designate of Sandoz Board of Directors Ruchika Sharma20 Feb 2023 3:30 PM ISTGhostine is an experienced business leader with a track record of growing and transforming businesses in competitive industries.
Novartis division Sandoz to set up Global Capability Centre in Hyderabad MD Bureau1 Feb 2023 1:30 PM ISTThe centre will initially have a workforce of 800 employees, with plans to increase to approximately 1,800 people in the near future.
